Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO LOESTRIN FE vs EMOQUETTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Oral contraception,Treatment of heavy menstrual bleeding (off-label),Dysmenorrhea (off-label),Acne vulgaris (off-label),Polycystic ovary syndrome (off-label)
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD),Panic disorder,Premenstrual dysphoric disorder (PMDD),Post-traumatic stress disorder (PTSD)
One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
Norethindrone: ~8 hours (range 5–12 h); Ethinyl estradiol: ~14 hours (range 10–20 h). Terminal half-life supports once-daily dosing with steady-state reached within 7–14 days.
Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment.
Ethinyl estradiol is metabolized primarily via CYP3A4, with hydroxylation and conjugation pathways. Norethindrone acetate is rapidly hydrolyzed to norethindrone, which is metabolized via reduction and conjugation. Ferrous fumarate is absorbed and utilized for hemoglobin synthesis.
EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette.
Renal (primarily as glucuronide conjugates of norethindrone and ethinyl estradiol): ~40% norethindrone metabolites, ~30% ethinyl estradiol metabolites; Fecal: ~30% norethindrone metabolites, ~40% ethinyl estradiol metabolites.
Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%).
Norethindrone: ~61% bound (primarily to albumin and SHBG); Ethinyl estradiol: ~97–98% bound (primarily to albumin, with ~1–2% free).
Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein.
Norethindrone: ~4 L/kg; Ethinyl estradiol: ~3–4 L/kg. Indicates extensive tissue distribution consistent with lipophilic steroids.
Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments.
Norethindrone: ~64% (oral); Ethinyl estradiol: ~45% (oral) due to first-pass metabolism, with high interindividual variability.
Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%.
No specific dosage adjustment required for renal impairment. Use with caution in patients with renal dysfunction due to potential fluid retention.
GFR 30-89 m L/min: no adjustment needed. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: use with caution; maximum dose 1 mg per day.
Contraindicated in patients with hepatic impairment, including acute or chronic liver disease, hepatic adenomas, or impaired liver function. No adjustment guidelines available; do not use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: one tablet orally once daily.
Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day.
Not indicated for use in postmenopausal women. No specific dosing adjustments for elderly patients as the drug is not used in this population.
Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
Increased risk of venous thromboembolism (VTE), myocardial infarction, and stroke, especially in smokers and women with hypertension or migraines,Adverse effects on bone density and potential for fractures with long-term use,Hepatic adenoma or hepatocellular carcinoma risk,Gallbladder disease,Glucose intolerance and insulin resistance,Elevated blood pressure,Cholestatic jaundice,Ocular lesions (e.g., retinal thrombosis),Depression,Iron overload in patients with hemochromatosis or chronic hemolytic anemia (due to ferrous fumarate)
Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles.
Current or history of thrombophlebitis, DVT, or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Breast carcinoma or other hormone-sensitive cancer,Hepatic tumor (benign or malignant) or active liver disease,Hypersensitivity to any component,Smoking in women over 35,Hemochromatosis or chronic hemolytic anemia (due to ferrous fumarate)
Concomitant use with MAOIs or within 14 days of MAOI therapy; Concomitant use with pimozide; Hypersensitivity to emoquette or any excipients; Use in patients with severe renal impairment (Cr Cl < 15 m L/min)
No specific food interactions are known for Lo Loestrin Fe. However, grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; it is prudent to advise against excessive grapefruit juice consumption. Iron tablets should be taken with food to reduce gastrointestinal upset; calcium-rich foods or supplements may decrease iron absorption, so separate iron intake from high-calcium meals by at least 2 hours.
No known food interactions. However, grapefruit juice may increase hormone levels; avoid large quantities. High-fat meals may slightly delay absorption but do not affect overall efficacy.
Pregnancy category X. Contraindicated in pregnant women due to risk of fetal harm, including cardiovascular defects and neural tube defects. Use during first trimester associated with oral clefts; second and third trimester use may lead to fetal hyperbilirubinemia and jaundice.
EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy.
Excreted in breast milk in small amounts; no reported adverse effects in infants. M/P ratio for ethinyl estradiol is approximately 0.04. Use with caution, especially during early postpartum period due to potential effects on milk production.
EMOQUETTE is excreted into breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in the nursing infant (e.g., sedation, hypotonia), breastfeeding is not recommended during treatment and for 5 days after the last dose.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended due to absence of safe therapeutic use.
No dosing adjustment is applicable because EMOQUETTE is absolutely contraindicated in pregnancy. If exposure occurs, immediate discontinuation is required.
Lo Loestrin Fe contains norethindrone acetate and ethinyl estradiol (1 mg/10 mcg) as the active hormonal pills, with a low iron (75 mg ferrous fumarate) supplement during the placebo week. It is the lowest-dose combination oral contraceptive available, which may minimize estrogen-related side effects. The regimen is 24 active pills, 2 placebo pills, then 2 iron pills, for a 28-day cycle. Spotting and breakthrough bleeding are common, especially in the first few cycles. It is indicated for contraception and not for emergency contraception. The iron tablets do not replace iron deficiency treatment. Contraindicated in patients with a history of thromboembolic disorders, liver disease, or known/suspected pregnancy.
EMOQUETTE is a novel oral contraceptive. Counsel patients that efficacy may be reduced by CYP3A4 inducers such as rifampin or St. John's Wort. Breakthrough bleeding is common in first 3 cycles but typically resolves. Administer at same time daily to maintain stable hormone levels.
Take one pill daily at the same time each day, preferably after the evening meal.,The first 24 pills are light blue (hormonal), the next 2 are white (placebo), and the last 2 are brown (iron tablets).,If you miss a dose: take it as soon as remembered, and if more than 12 hours late, use backup contraception for 7 days.,Common side effects: spotting, nausea, breast tenderness, and mood changes; these often improve after 3 months.,If you experience severe abdominal or chest pain, headache, or vision changes, seek medical attention.,Iron pills do not treat anemia; they only supplement daily iron needs.,Report any jaundice, depression, or high blood pressure to your healthcare provider.,Use an additional non-hormonal method if starting for the first time after the 5th day of your period.
Take one tablet at the same time every day, with or without food.,If you miss a dose, take it as soon as you remember and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in first few months.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Contact your healthcare provider if you experience leg pain, chest pain, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO LOESTRIN FE vs EMOQUETTE, answered by our medical review team.
LO LOESTRIN FE is a Combination Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.. EMOQUETTE is a Combination Oral Contraceptive that works by EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO LOESTRIN FE and EMOQUETTE depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO LOESTRIN FE is: One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).. The standard adult dose of EMOQUETTE is: 0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO LOESTRIN FE and EMOQUETTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO LOESTRIN FE is classified as Category C. Pregnancy category X. Contraindicated in pregnant women due to risk of fetal harm, including cardiovascular defects and neural tube defects. Use during first trimester associated w. EMOQUETTE is classified as Category C. EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.